| Identification | Back Directory | [Name]
2,6-Piperidinedione, 3-[4-[[1-[6-[4-[6'-(4-chlorophenyl)-1'-methylspiro[cyclopropane-1,4'-[4H][1,2,4]triazolo[4,3-a][1,4]benzodiazepin]-8'-yl]-1H-pyrazol-1-yl]hexyl]-4-piperidinyl]amino]-1,3-dihydro-1-oxo-2H-isoindol-2-yl]- | [CAS]
2154350-81-7 | [Synonyms]
CFT-743
2,6-Piperidinedione, 3-[4-[[1-[6-[4-[6'-(4-chlorophenyl)-1'-methylspiro[cyclopropane-1,4'-[4H][1,2,4]triazolo[4,3-a][1,4]benzodiazepin]-8'-yl]-1H-pyrazol-1-yl]hexyl]-4-piperidinyl]amino]-1,3-dihydro-1-oxo-2H-isoindol-2-yl]- | [Molecular Formula]
C46H49ClN10O3 | [MOL File]
2154350-81-7.mol | [Molecular Weight]
825.4 |
| Hazard Information | Back Directory | [Description]
CFT-743 is a potent BET degrader. In vitro, CFT-743 is more potent than a BET inhibitor (AZD5153) and a CDK9 inhibitor (dinaciclib) in 100% and 97% of 38 leukemia lines tested. In mice bearing HL60 tumors, CFT-743 has similar efficacy as dinaciclib (81% regression versus 99% tumor growth inhibition (TGI)). |
|
|